Alfacell Announces Resignation of President.BLOOMFIELD, N.J.--(BUSINESS WIRE)--Aug. 4, 1997--Alfacell Corp. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on : ACEL ACEL Australian Council for Educational Leaders (Australia) ACEL Aerospace Crew Equipment Laboratory ACEL Alternating Current Electro-Luminescent ) announced today the resignation of Michael C. Lowe, the company's president. The resignation was mutually agreed upon by Dr. Lowe and the company. Strategic and daily business operations will remain the responsibility of Kuslima Shogen, Alfacell's co-founder and chief executive officer and Gail E. Fraser, the company's chief financial officer and vice president of finance. Pharmaceutical executives Dr. Stephen K. Carter, formerly senior vice president of Bristol-Myers Squibb for worldwide clinical research and development and Donald R. Conklin, former president of Schering-Plough Pharmaceuticals, have recently joined Alfacell's board of directors and, in addition to their board responsibilities, will be actively advising the company in the areas of product and business development. Alfacell Corp., the world leader in the development of ribonucleases (RNases) for therapeutic applications, is currently testing ONCONASE(R), an investigational antitumor an·ti·tu·mor also an·ti·tu·mor·al adj. Counteracting or preventing the formation of malignant tumors; anticancer. Adj. 1. agent, against solid tumors in various clinical trials. ONCONASE is the smallest known member of the superfamily superfamily /su·per·fam·i·ly/ (soo´per-fam?i-le) 1. a taxonomic category between an order and a family. 2. of pancreatic RNases, and is the only cytotoxic RNase currently in clinical trials. The company is currently conducting multi-center Phase II and III clinical trials of ONCONASE against a number of solid tumors, including pancreatic adenocarcinoma, malignant mesothelioma, advanced renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. , and prostrate pros·trate tr.v. pros·trat·ed, pros·trat·ing, pros·trates 1. To put or throw flat with the face down, as in submission or adoration: cancer. Alfacell is located in Bloomfield, and is traded on NASDAQ under the symbol "ACEL." CONTACT: Alfacell Corp., Bloomfield Donna Brasko, Director of Corporate Communications, 973/748-8082 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion